Citigroup Inc. and its affiliates, including Citigroup Global Markets Inc., Citigroup Financial Products Inc., and Citigroup Global Markets Holdings Inc., have filed a Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a beneficial ownership of 1,000,036 shares of common stock in Eagle Pharmaceuticals, Inc. This represents 7.7% of the class, as of the event date of September 30, 2024. The filing, made under Rule 13d-1(b), signifies that the shares were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of the issuer. The principal business office for all reporting entities is located at 388 Greenwich Street, New York, NY 10013. Citigroup Inc. and its subsidiaries have affirmed that the information provided in the statement is true and correct to the best of their knowledge.

Citigroup Inc. and its affiliates, including Citigroup Global Markets Inc., Citigroup Financial Products Inc., and Citigroup Global Markets Holdings Inc., have filed a Schedule 13G with the Securities and Exchange Commission on November 12, 2024, indicating a beneficial ownership of 1,000,036 shares of common stock in Eagle Pharmaceuticals, Inc. This represents 7.7% of the class, as of the event date of September 30, 2024. The filing, made under Rule 13d-1(b), signifies that the shares were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of the issuer. The principal business office for all reporting entities is located at 388 Greenwich Street, New York, NY 10013. Citigroup Inc. and its subsidiaries have affirmed that the information provided in the statement is true and correct to the best of their knowledge.